illumin Announces Intention To Voluntarily Delist From NASDAQ

 illumin Holdings Inc. (TSX:ILLM, NASDAQ:ILLM) ("illumin" or the "Corporation") today announced that it has notified the NASDAQ Stock Market LLC ("NASDAQ") of its intention to

 illumin Holdings Inc. (TSX:ILLM, NASDAQ:ILLM) (“illumin” or the “Corporation”) today announced that it has notified the NASDAQ Stock Market LLC (“NASDAQ“) of its intention to voluntarily delist its common shares (“Shares“) from The Nasdaq Stock Market (“NASDAQ“). Shares will continue to trade on the Toronto Stock Exchange (“TSX“).
 

With the majority of its Shares trading on the TSX, illumin believes the costs and administrative requirements associated with maintaining a dual listing are not justified at this time. The decision to voluntarily delist the Shares from NASDAQ was first announced by the Corporation in a press release on July 26, 2023.

The Corporation plans to file a Form 25 with the Securities Exchange Commissions (the “SEC“) and expects that its Shares will cease trading on NASDAQ on or about September 11, 2023. The Corporation’s financial statements, press releases and other information will continue to be available on SEDAR+ at www.sedarplus.com, on EDGAR at www.sec.gov and on its website at illumin.com.

Total
0
Shares
Related Posts
Read More

On May 14, 2024, Paragon Therapeutics Announced A License Agreement Granting Spyre Therapeutics An Exclusive License To Certain Antibodies And Products Targeting α4SS7 Integrin And Tl1A, Paragon Will Up To $22M In Milestone Payments-8K

Paragon will provide the Company with an exclusive license to its patents covering the related antibody, the method of use and its method of manufacture. Paragon will not conduct any new campaigns that generate

SYRE